Αρχική World News FDA Approves Zidesamtinib for ROS1-positive Non-Small Cell Lung Cancer World News FDA Approves Zidesamtinib for ROS1-positive Non-Small Cell Lung Cancer Από Ogkologos - 16 Σεπτεμβρίου, 2026 141 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARROS-1 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR One year on: How has COVID-19 affected cancer services? 14 Μαΐου, 2021 ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ 8 Μαρτίου, 2019 When Ovarian Cancer Returns, Surgery May Be a Good Choice for... 12 Ιανουαρίου, 2022 ‘Inside Edition’ Anchor Thanks Viewer For Pointing Out Lump That Turned... 24 Απριλίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung... Do Birth Control Pills Impact My Cancer Risk? School Teacher’s Breast Cancer Journey Inspired Her to Move to Australia... ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at...